Overview

Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

Status:
Not yet recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1, 6-month, open-label, multi-center study in parallel groups of randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and Vivitrol intramuscular depot naltrexone injection.

Phase:

Phase 1

Details

Lead Sponsor:

BioCorRx Pharmaceuticals, Inc.

Collaborator:

National Institute on Drug Abuse (NIDA)

Treatments:

Naltrexone